Andromeda Surgical

Executive Summary

Andromeda Surgical is a privately held medical technology company headquartered in Irvine, CA, founded in 2018. The company is developing an intelligent, software-first surgical platform that integrates AI-guided spatial navigation and autonomous assistance. Initially focused on endourology, the platform aims to become the central intelligence layer for the operating room, enabling surgeons to perform procedures with greater precision and efficiency. By combining real-time data analysis with robotic-like guidance, Andromeda addresses key challenges in minimally invasive surgery, such as variability in outcomes and surgeon fatigue. The endourology market represents a significant opportunity, driven by the increasing prevalence of kidney stones and other urinary tract conditions. Andromeda's technology has the potential to reduce procedural times, improve consistency, and lower complication rates. While the company is still in an early stage, likely preclinical or early clinical, its innovative approach and strong intellectual property position it for growth. Key near-term objectives include securing Series A funding, initiating first clinical studies, and pursuing regulatory clearance. With a visionary platform and a large addressable market, Andromeda Surgical is well-positioned to disrupt the surgical robotics space.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement70% success
• Q4 2026First Clinical Use of AI-Guided Platform in Endourology60% success
• Q1 2027FDA 510(k) Submission for Surgical Navigation System50% success